R. Tedde

发表

Insulinemia and blood pressure. Relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment.

L. Sechi, A. Pacifico, A. Pacifico, 1990, American journal of hypertension.

Hyperinsulinemia and hypertension. Do intestinal hormones play a role?

F. Bilotta, G. Realdi, A. Melis, 1995, American journal of hypertension.

AND ESSENTIAL HYPERTENSIVE SUBJECTS WITH AND WITHOUT OVERWEIGHT. ERYTHROCYTE SODIUM METABOLISM IN NORMOTENSIVE .

A. Melis, R. Tedde, A. Pala, 1991 .

Serum insulin, insulin sensitivity, and erythrocyte sodium metabolism in normotensive and essential hypertensive subjects with and without overweight.

A. Melis, L. Sechi, A. Marigliano, 1991, Clinical and experimental hypertension. Part A, Theory and practice.

Insulin hypersecretion: a distinctive feature between essential and secondary hypertension.

A. Melis, L. Sechi, R. Tedde, 1992, Metabolism: clinical and experimental.

Antihypertensive effect of insulin reduction in diabetic-hypertensive patients.

L. Sechi, A. Marigliano, R. Tedde, 1989, American journal of hypertension.

Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess.

R. Tedde, S. Ulick, J. Z. Wang, 1992, The Journal of clinical endocrinology and metabolism.

Twice‐A‐Day Quadruple Therapy for Eradication of Helicobacter pylori in the Elderly

G. Realdi, M. Dore, G. Delitala, 2006, Helicobacter.

Molecular Basis for Hypertension in the “Type II Variant” of Apparent Mineralocorticoid Excess

C. Shackleton, F. Mantero, P. Stewart, 1998 .

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

C. Shackleton, F. Mantero, P. Stewart, 1997, American journal of human genetics.

Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess.

F. Mantero, R. Tedde, S. Ulick, 1990, The Journal of clinical endocrinology and metabolism.

Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?

G. Delitala, C. Shackleton, R. Tedde, 2000, Journal of endocrinological investigation.

Apparent mineralocorticoid excess: Type I and type II

C. Shackleton, F. Mantero, P. Stewart, 1996, Steroids.

Evidence for Cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess

A. Melis, R. Tedde, A. Pala, 1992, Journal of endocrinological investigation.

Apparent mineralocorticoid excess type II

G. Arnaldi, F. Mantero, G. Opocher, 1994, Steroids.

Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.

N. Glorioso, F. Monaco, P. Dessı̀-Fulgheri, 1978, Journal of neurology, neurosurgery, and psychiatry.

Evidence for a direct and non-receptor-mediated action of 5HT2 antagonists on transmembrane cation transport systems

A. Melis, L. Sechi, S. Masia, 2004, Cardiovascular Drugs and Therapy.

Acute renal failure in paroxysmal nocturnal haemoglobinuria with splanchnic venous thromboses.

L. Sechi, A. Marigliano, R. Tedde, 1989, Clinical and laboratory haematology.

Sublingual and intravenous ketanserin versus sublingual nifedipine in the treatment of severe hypertension: a randomized study.

A. Melis, L. Sechi, R. Tedde, 1989, Clinical Therapeutics.

In vitro action of insulin on erythrocyte sodium transport mechanisms: its possible role in the pathogenesis of arterial hypertension.

L. Sechi, A. Marigliano, R. Tedde, 1988, Clinical and experimental hypertension. Part A, Theory and practice.

Venous thrombosis and acute renal failure in paroxysmal nocturnal haemoglobinuria.

L. Sechi, A. Marigliano, R. Tedde, 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.